Clinical Trials Search

Official Title: Testing What Happens When An Immunotherapy Drug (Pembrolizumab) Is Added To Radiation Or Given By Itself Compared To The Usual Treatment Of Chemotherapy With Radiation After You Have Had Surgery For Your Recurrent Squamous Cell Carcinoma Of The Head And Neck

Study Purpose: To compare usual approach (chemotherapy plus radiation) to pembrolizumab alone and pembrolizumab in combination with radiation after having head and neck cancer surgically removed.

Status: Recruiting

Official Title: Phase II Study of Osimertinib in Advanced NSCLC Patients with Exon 20 Mutations in EGFR

Study Purpose: To evaluate the best objective response rate of AZD9291 (osimertinib) among patients with EGFR exon 20 insertions.

Status: Recruiting

Official Title: Randomized phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma

Study Purpose: To compare any good and bad effects of giving three drugs- ipilimumab, nivolumab, and sargramostim at the same time compared to just ipilimumab and nivolumab together.

Status: Recruiting

Official Title: Testing Pembrolizumab versus Observation in Patients with Merkel Cell Carcinoma after Surgery

Study Purpose: To see if the chance of cancer growing back can be lowered by adding the study drug, pembrolizumab, after surgery.

Status: Suspended

Official Title: Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR alpha-high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA)

Study Purpose: To compare progression-free survival after platinum-based chemotherapy (doublet) plus bevacizumab and randomized to maintenance mirvetuxemab sorvtansine (MIRV) plus bevacizumab (Arm 1) versus bevacizumab alone (Arm 2)

Status: Recruiting

Official Title: A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)

Study Purpose: To investigate the efficacy and safety of luveltamab tazevibulin in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.

Status: Recruiting

Official Title: Blood and Tissue Procurement Protocol for Product Development and Research

Study Purpose: To collect cancerous tissue/fluid and blood samples to store and use for research purposes.

Status: Recruiting

Official Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05 / OptimICE-RD)

Status: Recruiting

Official Title: Randomized, Double-Blind, International Multicenter, Phase III Study to Evaluate the Anti-Tumor Efficacy and Safety of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody) or Placebo in Combination with Chemotherapy (Carboplatin/Cisplatin-Etoposide) and Concurrent Radiotherapy in Patients with Limited-Stage Small Cell Lung Cancer (LS-SCLC)

Study Purpose: To evaluate the effectiveness of HLX10 in combination with chemotherapy and radiation.  

Status: Pending

Official Title: A randomized trial of ultrasound-facilitated, catheter-directed, thrombolysis versus anticoagulation for acute intermediate-high risk pulmonary embolism: The higher-risk pulmonary embolism thrombolysis study.

Study Purpose: To assess whether ultrasound-facilitated, catheter-directed, thrombolysis and anticoagulation are associated with a significant reduction in the composite outcome of pulmonary embolism (PE)-related mortality, cardiorespiratory decompensation or collapse, or nonfatal symptomatic and objectively confirmed recurrence of PE compared to anticoagulation alone within seven days of randomization.

Status: Recruiting